Consultancy: Senior consultant to supervise the pharmaceutical expenditure data collection in the Depok district in Indonesia
Results for Development, Indonesia
Experience
1 Year
Salary
0 - 0
Job Type
Job Shift
Job Category
Traveling
No
Career Level
Telecommute
No
Qualification
As mentioned in job details
Total Vacancies
1 Job
Posted on
Feb 8, 2022
Last Date
Mar 8, 2022
Location(s)
Job Description
Results for Development (R4D) is a leading non-profit global development partner. We collaborate with change agents around the world government officials, civil society leaders and social innovators to create strong systems that support healthy, educated people. We help our partners move from knowing their goal to knowing how to reach it. We combine global expertise in health, education and nutrition with analytic rigor, practical support for decision-making and implementation and access to peer problem-solving networks. Together with our partners, we build self-sustaining systems that serve everyone and deliver lasting results. Then we share what we learn so others can achieve results for development, too.
We have a unique and vibrant culture at R4D. Diversity, equity and inclusion are at the heart of our work environment and help advance our mission. Diversityof ideas, identities, perspectives and backgroundsis vital to who we are and what we do. We seek people who embrace these values and will help reinforce them. Our work culture is collaborative, creative and entrepreneurial. We operate based on trust and respect. Teams across the organization frequently collaborate on programmatic work and support each other in continuously building a better R4D.
1. Introduction and Background: Funded by the U.S. Agency for International Development (USAID), the Medicines, Technologies, and Pharmaceutical Services (MTaPS) Program, implemented by Management Sciences for Health and partners including Results for Development (R4D), provides pharmaceutical system strengthening assistance for sustained improvements in health system performance and to advance USAID’S goals of preventing child and maternal deaths, controlling the HIV/AIDS epidemic, and combating infectious disease threats, as well as expanding essential health coverage.
The goal of the global, five-year (20182023) program is to enable low- and middle-income countries to strengthen their pharmaceutical systems to ensure sustainable access to and appropriate use of safe, effective, quality-assured, and affordable essential medicines and medicine-related pharmaceutical services.
To achieve this goal, the MTAPS program has the following objectives:· Strengthen pharmaceutical sector governance · Increase institutional and human resource capacity for pharmaceutical management and services, including regulation of medical products· Improve availability and use of pharmaceutical information for decision making increased and global learning agenda · Optimize pharmaceutical sector financing, including resource allocation and use· Enhance pharmaceutical services, including product availability and patient-centered care to achieve desired health outcomes
The purpose of MTaPS is to provide pharmaceutical system strengthening assistance for sustained improvements in health system performance, and to advance USAID’s goals of Preventing Child and Maternal Deaths, Controlling the HIV/AIDS Epidemic, and Combatting Infectious Disease Threats, as well as expanding essential health coverage. In July 2019, MTaPS visited Indonesia to assess areas where the program could support the government in its efforts toward sustainable financing for universal health coverage (UHC).
Increasing Accuracy of Pharmaceutical Expenditure Tracking Many countries lack capacity to efficiently collect, analyze, and use data on pharmaceutical expenditures in order to ensure value-for-money of spending. Health Accounts teams often need support to accurately measure pharmaceuticals spending using the System of Health Accounts (SHA) 2011 framework. Sometimes the data exist but are not compiled or analyzed in a meaningful way. However, the SHA 2011 implementation guidelines provide limited guidance on tracking of pharmaceutical expenditures. Stakeholders making decisions about pharmaceuticals and other policy actors in the health system need more accurate data on pharmaceutical spending and greater capacity to use such data to conduct secondary analysis to inform decision-making around spending on pharmaceuticals. Supplementary guidelines for SHA 2011 exist for specific programs such as family planning, immunization, and maternal and child health. For pharmaceutical expenditure tracking, preliminary work has been done to develop an operational guide.
In this activity, MTaPS will contribute expertise to customize the Health Accounts methodology to produce higher quality and detailed data on pharmaceutical spending in Indonesia. This will include determining how expenditure on different medicines can be collected, compiled, and classified to align with the Health Accounts methodology; identifying the type of summary data
We have a unique and vibrant culture at R4D. Diversity, equity and inclusion are at the heart of our work environment and help advance our mission. Diversityof ideas, identities, perspectives and backgroundsis vital to who we are and what we do. We seek people who embrace these values and will help reinforce them. Our work culture is collaborative, creative and entrepreneurial. We operate based on trust and respect. Teams across the organization frequently collaborate on programmatic work and support each other in continuously building a better R4D.
1. Introduction and Background: Funded by the U.S. Agency for International Development (USAID), the Medicines, Technologies, and Pharmaceutical Services (MTaPS) Program, implemented by Management Sciences for Health and partners including Results for Development (R4D), provides pharmaceutical system strengthening assistance for sustained improvements in health system performance and to advance USAID’S goals of preventing child and maternal deaths, controlling the HIV/AIDS epidemic, and combating infectious disease threats, as well as expanding essential health coverage.
The goal of the global, five-year (20182023) program is to enable low- and middle-income countries to strengthen their pharmaceutical systems to ensure sustainable access to and appropriate use of safe, effective, quality-assured, and affordable essential medicines and medicine-related pharmaceutical services.
To achieve this goal, the MTAPS program has the following objectives:· Strengthen pharmaceutical sector governance · Increase institutional and human resource capacity for pharmaceutical management and services, including regulation of medical products· Improve availability and use of pharmaceutical information for decision making increased and global learning agenda · Optimize pharmaceutical sector financing, including resource allocation and use· Enhance pharmaceutical services, including product availability and patient-centered care to achieve desired health outcomes
The purpose of MTaPS is to provide pharmaceutical system strengthening assistance for sustained improvements in health system performance, and to advance USAID’s goals of Preventing Child and Maternal Deaths, Controlling the HIV/AIDS Epidemic, and Combatting Infectious Disease Threats, as well as expanding essential health coverage. In July 2019, MTaPS visited Indonesia to assess areas where the program could support the government in its efforts toward sustainable financing for universal health coverage (UHC).
Increasing Accuracy of Pharmaceutical Expenditure Tracking Many countries lack capacity to efficiently collect, analyze, and use data on pharmaceutical expenditures in order to ensure value-for-money of spending. Health Accounts teams often need support to accurately measure pharmaceuticals spending using the System of Health Accounts (SHA) 2011 framework. Sometimes the data exist but are not compiled or analyzed in a meaningful way. However, the SHA 2011 implementation guidelines provide limited guidance on tracking of pharmaceutical expenditures. Stakeholders making decisions about pharmaceuticals and other policy actors in the health system need more accurate data on pharmaceutical spending and greater capacity to use such data to conduct secondary analysis to inform decision-making around spending on pharmaceuticals. Supplementary guidelines for SHA 2011 exist for specific programs such as family planning, immunization, and maternal and child health. For pharmaceutical expenditure tracking, preliminary work has been done to develop an operational guide.
In this activity, MTaPS will contribute expertise to customize the Health Accounts methodology to produce higher quality and detailed data on pharmaceutical spending in Indonesia. This will include determining how expenditure on different medicines can be collected, compiled, and classified to align with the Health Accounts methodology; identifying the type of summary data
Job Specification
Job Rewards and Benefits
More Jobs like this Job
Results for Development
Information Technology and Services - Washington, United States
© Copyright 2004-2024 Mustakbil.com Indonesia's No 1 Jobs Site, All Right Reserved.